Thomas Powles, MBBS, MRCP, MD, joins the Oncology Brothers to discuss the study design and results of the EV-302 trial investigating enfortumab vedotin plus pembrolizumab in untreated advanced urothelial carcinoma.
EV-302: Enfortumab Vedotin and Pembrolizumab
The Oncology Brothers are joined by Thomas Powles, MBBS, MRCP, MD, to discuss the role of enfortumab vedotin plus pembrolizumab in the bladder cancer treatment landscape.
A comprehensive discussion on treatment-related adverse events seen in patients receiving enfortumab vedotin and pembrolizumab.
Following a discussion centered on the EV-302 study, Thomas Powles, MBBS, MRCP, MD, and the Oncology Brothers discuss the role of circulating tumor DNA in urothelial cancer.